BioCryst PharmaceuticalsBCRX
Market Cap: $1.65B
About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Employees: 531
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
25% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 67
20% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]
16% more capital invested
Capital invested by funds: $931M [Q1] → $1.08B (+$146M) [Q2]
3% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 40
0% more funds holding
Funds holding: 236 [Q1] → 237 (+1) [Q2]
3% less call options, than puts
Call options by funds: $8.76M | Put options by funds: $9.04M
4.37% less ownership
Funds ownership: 88.81% [Q1] → 84.44% (-4.37%) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
JMP Securities Jonathan Wolleben 42% 1-year accuracy 30 / 71 met price target | 101%upside $16 | Market Outperform Maintained | 6 Aug 2024 |
Barclays Gena Wang 42% 1-year accuracy 10 / 24 met price target | 12%downside $7 | Equal-Weight Maintained | 6 Aug 2024 |
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 25%upside $10 | Outperform Reiterated | 6 Aug 2024 |
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 77 / 166 met price target | 276%upside $30 | Buy Reiterated | 6 Aug 2024 |
Financial journalist opinion
Based on 3 articles about BCRX published over the past 30 days